ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CELU vs CRVO // NET PROFIT MARGIN

Celularity Inc. (Class A) (NASDAQ) VS. CervoMed Inc. (NASDAQ) • 15-METRIC TALLY: CELU 3 — CRVO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CELU VS. CRVO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CELU CRVO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 24.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -51.00% -58.90% +7.90 CELU /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 2/9 -1.00 CRVO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.9 24.1 +11.86 CELU /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $27.6M $26.5M $1.1M CELU /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CELU REV CRVO REV CELU GROSS % CRVO GROSS % CELU FCF CRVO FCF
FY 2025 $26.6M $4.0M 24.4% — -$13.3M -$23.4M
FY 2024 $54.2M $9.7M 72.4% — -$6.6M -$16.5M
FY 2023 $22.8M $7.1M — — -$38.7M -$7.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CELU // BETA —
CRVO // BETA —